C
GSK plc
GSK
$40.71
$0.6551.64%
C
Hold
3/3/2025Upgraded
GSK plc (GSK) was upgraded to C- from D+ on 3/3/2025 due to a large increase in the growth index, efficiency index and volatility index. Net income increased 802.46% from -$75.48M to $530.19M, earnings per share increased from -$0.0185 to $0.1288, and EBIT increased 47.1% from $867.97M to $1.28B.
GSK plc (GSK) was upgraded to C- from D+ on 3/3/2025 due to a large increase in the growth index, efficiency index and volatility index. Net income increased 802.46% from -$75.48M to $530.19M, earnings per share increased from -$0.0185 to $0.1288, and EBIT increased 47.1% from $867.97M to $1.28B.
D
Sell
2/10/2025Downgrade
GSK plc (GSK) was downgraded to D+ from C- on 2/10/2025 due to a noticeable decline in the total return index and volatility index.
GSK plc (GSK) was downgraded to D+ from C- on 2/10/2025 due to a noticeable decline in the total return index and volatility index.
C
Hold
10/31/2024Downgrade
GSK plc (GSK) was downgraded to C- from C on 10/31/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.3595 to -$0.0185, net income declined 105.1% from $1.48B to -$75.48M, and EBIT declined 68.94% from $2.79B to $867.97M.
GSK plc (GSK) was downgraded to C- from C on 10/31/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.3595 to -$0.0185, net income declined 105.1% from $1.48B to -$75.48M, and EBIT declined 68.94% from $2.79B to $867.97M.
C
Hold
10/10/2023Upgraded
GSK plc (GSK) was upgraded to C from C- on 10/10/2023 due to an increase in the total return index.
GSK plc (GSK) was upgraded to C from C- on 10/10/2023 due to an increase in the total return index.
C
Hold
8/3/2023Downgrade
GSK plc (GSK) was downgraded to C- from C on 8/3/2023 due to a decline in the growth index and volatility index.
GSK plc (GSK) was downgraded to C- from C on 8/3/2023 due to a decline in the growth index and volatility index.
C
Hold
6/15/2023Upgraded
GSK plc (GSK) was upgraded to C from C- on 6/15/2023 due to an increase in the volatility index, total return index and solvency index. Debt to equity declined from 1.85 to 1.74, and the quick ratio increased from 0.66 to 0.68.
GSK plc (GSK) was upgraded to C from C- on 6/15/2023 due to an increase in the volatility index, total return index and solvency index. Debt to equity declined from 1.85 to 1.74, and the quick ratio increased from 0.66 to 0.68.
C
Hold
1/24/2023Upgraded
GSK plc (GSK) was upgraded to C- from D+ on 1/24/2023 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.2595 to $2.9711, EBIT increased 29.43% from $2.15B to $2.78B, and total revenue increased 5.86% from $8.71B to $9.22B.
GSK plc (GSK) was upgraded to C- from D+ on 1/24/2023 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.2595 to $2.9711, EBIT increased 29.43% from $2.15B to $2.78B, and total revenue increased 5.86% from $8.71B to $9.22B.
D
Sell
10/19/2022Downgrade
GSK plc (GSK) was downgraded to D+ from C- on 10/19/2022 due to a decline in the total return index and volatility index.
GSK plc (GSK) was downgraded to D+ from C- on 10/19/2022 due to a decline in the total return index and volatility index.
C
Hold
8/19/2022Downgrade
GSK plc (GSK) was downgraded to C- from C on 8/19/2022 due to a large decline in the total return index and volatility index.
GSK plc (GSK) was downgraded to C- from C on 8/19/2022 due to a large decline in the total return index and volatility index.
C
Hold
8/2/2022Downgrade
GSK plc (GSK) was downgraded to C from C+ on 8/2/2022 due to a decline in the volatility index and total return index.
GSK plc (GSK) was downgraded to C from C+ on 8/2/2022 due to a decline in the volatility index and total return index.
C
Hold
7/28/2022Downgrade
GSK plc (GSK) was downgraded to C+ from B- on 7/28/2022 due to a significant decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.94 to 0.35, earnings per share declined from $0.5962 to $0.2595, and total revenue declined 9.64% from $9.64B to $8.71B.
GSK plc (GSK) was downgraded to C+ from B- on 7/28/2022 due to a significant decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.94 to 0.35, earnings per share declined from $0.5962 to $0.2595, and total revenue declined 9.64% from $9.64B to $8.71B.
B
Buy
7/19/2022Downgrade
GSK plc (GSK) was downgraded to B- from B on 7/19/2022 due to a noticeable decline in the total return index and volatility index.
GSK plc (GSK) was downgraded to B- from B on 7/19/2022 due to a noticeable decline in the total return index and volatility index.
B
Buy
5/5/2022Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 5/5/2022 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.1998 to $0.4773, the quick ratio increased from 0.52 to 0.94, and EBIT increased 33.27% from $2.28B to $3.04B.
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 5/5/2022 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.1998 to $0.4773, the quick ratio increased from 0.52 to 0.94, and EBIT increased 33.27% from $2.28B to $3.04B.
B
Buy
4/18/2022Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 4/18/2022 due to a noticeable increase in the total return index.
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 4/18/2022 due to a noticeable increase in the total return index.
C
Hold
3/4/2022Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 3/4/2022 due to a major decline in the growth index, volatility index and solvency index. EBIT declined 37.63% from $3.66B to $2.28B, earnings per share declined from $0.3183 to $0.1998, and the quick ratio declined from 0.53 to 0.52.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 3/4/2022 due to a major decline in the growth index, volatility index and solvency index. EBIT declined 37.63% from $3.66B to $2.28B, earnings per share declined from $0.3183 to $0.1998, and the quick ratio declined from 0.53 to 0.52.
B
Buy
11/3/2021Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C on 11/3/2021 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 95.43% from $1.81B to $3.53B, EBIT increased 32.37% from $2.77B to $3.66B, and total revenue increased 10.55% from $11.31B to $12.51B.
GlaxoSmithKline plc (GSK) was upgraded to B- from C on 11/3/2021 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 95.43% from $1.81B to $3.53B, EBIT increased 32.37% from $2.77B to $3.66B, and total revenue increased 10.55% from $11.31B to $12.51B.
C
Hold
10/6/2021Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 10/6/2021 due to a decline in the volatility index.
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 10/6/2021 due to a decline in the volatility index.
C
Hold
9/15/2021Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 9/15/2021 due to a noticeable increase in the volatility index, efficiency index and total return index. Net income increased 31.81% from $1.48B to $1.95B, and total capital increased 0.5% from $64.81B to $65.14B.
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 9/15/2021 due to a noticeable increase in the volatility index, efficiency index and total return index. Net income increased 31.81% from $1.48B to $1.95B, and total capital increased 0.5% from $64.81B to $65.14B.
C
Hold
9/10/2020Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 9/10/2020 due to a decline in the total return index and efficiency index. Total capital declined 1.08% from $64.87B to $64.17B.
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 9/10/2020 due to a decline in the total return index and efficiency index. Total capital declined 1.08% from $64.87B to $64.17B.
C
Hold
6/26/2020Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 6/26/2020 due to an increase in the dividend index and valuation index.
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 6/26/2020 due to an increase in the dividend index and valuation index.
C
Hold
5/1/2020Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 5/1/2020 due to a large decline in the growth index, dividend index and total return index. Operating cash flow declined 72.22% from $4.44B to $1.23B, and EBIT declined 7.88% from $2.8B to $2.58B.
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 5/1/2020 due to a large decline in the growth index, dividend index and total return index. Operating cash flow declined 72.22% from $4.44B to $1.23B, and EBIT declined 7.88% from $2.8B to $2.58B.
C
Hold
3/16/2020Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B on 3/16/2020 due to a noticeable decline in the volatility index and total return index.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B on 3/16/2020 due to a noticeable decline in the volatility index and total return index.
B
Buy
3/6/2020Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 3/6/2020 due to an increase in the volatility index, dividend index and solvency index. Debt to equity declined from 2.81 to 2.51, and the quick ratio increased from 0.5 to 0.51.
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 3/6/2020 due to an increase in the volatility index, dividend index and solvency index. Debt to equity declined from 2.81 to 2.51, and the quick ratio increased from 0.5 to 0.51.
B
Buy
2/28/2020Downgrade
GlaxoSmithKline plc (GSK) was downgraded to B- from B on 2/28/2020 due to a noticeable decline in the volatility index and total return index.
GlaxoSmithKline plc (GSK) was downgraded to B- from B on 2/28/2020 due to a noticeable decline in the volatility index and total return index.
B
Buy
10/31/2019Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 10/31/2019 due to a major increase in the solvency index, growth index and total return index. Operating cash flow increased 73.58% from $1.79B to $3.1B, debt to equity declined from 9.37 to 2.81, and earnings per share increased from $0.2482 to $0.3821.
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 10/31/2019 due to a major increase in the solvency index, growth index and total return index. Operating cash flow increased 73.58% from $1.79B to $3.1B, debt to equity declined from 9.37 to 2.81, and earnings per share increased from $0.2482 to $0.3821.
B
Buy
9/20/2019Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 9/20/2019 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 106.77% from $863.78M to $1.79B, earnings per share increased from $0.2176 to $0.2482, and total revenue increased 0.6% from $9.98B to $10.04B.
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 9/20/2019 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 106.77% from $863.78M to $1.79B, earnings per share increased from $0.2176 to $0.2482, and total revenue increased 0.6% from $9.98B to $10.04B.
C
Hold
7/5/2019Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 7/5/2019 due to a decline in the total return index, valuation index and dividend index.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 7/5/2019 due to a decline in the total return index, valuation index and dividend index.
B
Buy
6/19/2019Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 6/19/2019 due to a noticeable increase in the volatility index, dividend index and valuation index.
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 6/19/2019 due to a noticeable increase in the volatility index, dividend index and valuation index.
C
Hold
5/2/2019Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 5/2/2019 due to a significant increase in the growth index, valuation index and total return index.
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 5/2/2019 due to a significant increase in the growth index, valuation index and total return index.
C
Hold
8/14/2018Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 8/14/2018 due to an increase in the volatility index, solvency index and valuation index.
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 8/14/2018 due to an increase in the volatility index, solvency index and valuation index.
C
Hold
7/26/2018Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 7/26/2018 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from -250.86 to 7.87, earnings per share declined from $0.1545 to $0.1212, and total revenue declined 0.99% from $10.05B to $9.95B.
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 7/26/2018 due to a noticeable decline in the growth index, solvency index and valuation index. Debt to equity increased from -250.86 to 7.87, earnings per share declined from $0.1545 to $0.1212, and total revenue declined 0.99% from $10.05B to $9.95B.
C
Hold
5/21/2018Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 5/21/2018 due to an increase in the volatility index, dividend index and solvency index.
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 5/21/2018 due to an increase in the volatility index, dividend index and solvency index.
C
Hold
4/26/2018Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 4/26/2018 due to a noticeable decline in the valuation index, dividend index and efficiency index.
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 4/26/2018 due to a noticeable decline in the valuation index, dividend index and efficiency index.
C
Hold
3/28/2018Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 3/28/2018 due to a noticeable increase in the solvency index, valuation index and volatility index. Debt to equity declined from 14.36 to -246.15.
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 3/28/2018 due to a noticeable increase in the solvency index, valuation index and volatility index. Debt to equity declined from 14.36 to -246.15.
C
Hold
12/27/2017Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 12/27/2017 due to a decline in the volatility index and total return index.
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 12/27/2017 due to a decline in the volatility index and total return index.
C
Hold
10/26/2017Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 10/26/2017 due to a large increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.0474 to $0.322, operating cash flow increased 92.48% from $1.29B to $2.48B, and debt to equity declined from 22.93 to 14.36.
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 10/26/2017 due to a large increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.0474 to $0.322, operating cash flow increased 92.48% from $1.29B to $2.48B, and debt to equity declined from 22.93 to 14.36.
C
Hold
7/27/2017Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 7/27/2017 due to a large decline in the growth index, solvency index and dividend index. Earnings per share declined from $0.264 to -$0.0474, debt to equity increased from 10.59 to 22.93, and EBIT declined 101.11% from $2.3B to -$25.6M.
GlaxoSmithKline plc (GSK) was downgraded to C- from C on 7/27/2017 due to a large decline in the growth index, solvency index and dividend index. Earnings per share declined from $0.264 to -$0.0474, debt to equity increased from 10.59 to 22.93, and EBIT declined 101.11% from $2.3B to -$25.6M.
C
Hold
5/4/2017Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 5/4/2017 due to a major increase in the growth index, valuation index and solvency index. EBIT increased 799.46% from $255.86M to $2.3B, earnings per share increased from $0.065 to $0.264, and debt to equity declined from 16.78 to 10.59.
GlaxoSmithKline plc (GSK) was upgraded to C from C- on 5/4/2017 due to a major increase in the growth index, valuation index and solvency index. EBIT increased 799.46% from $255.86M to $2.3B, earnings per share increased from $0.065 to $0.264, and debt to equity declined from 16.78 to 10.59.
C
Hold
4/11/2017Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 4/11/2017 due to an increase in the total return index and volatility index.
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 4/11/2017 due to an increase in the total return index and volatility index.
D
Sell
3/16/2017Downgrade
GlaxoSmithKline plc (GSK) was downgraded to D+ from C- on 3/16/2017 due to a noticeable decline in the growth index and efficiency index. EBIT declined 90.9% from $2.81B to $255.76M, earnings per share declined from $0.2166 to $0.065, and net income declined 69.92% from $1.06B to $319.07M.
GlaxoSmithKline plc (GSK) was downgraded to D+ from C- on 3/16/2017 due to a noticeable decline in the growth index and efficiency index. EBIT declined 90.9% from $2.81B to $255.76M, earnings per share declined from $0.2166 to $0.065, and net income declined 69.92% from $1.06B to $319.07M.
C
Hold
3/13/2017Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 3/13/2017 due to an increase in the total return index and volatility index.
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 3/13/2017 due to an increase in the total return index and volatility index.
D
Sell
1/10/2017Downgrade
GlaxoSmithKline plc (GSK) was downgraded to D+ from C- on 1/10/2017 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from 36.82 to 141.43.
GlaxoSmithKline plc (GSK) was downgraded to D+ from C- on 1/10/2017 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from 36.82 to 141.43.
C
Hold
8/12/2016Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 8/12/2016 due to an increase in the efficiency index, dividend index and total return index.
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 8/12/2016 due to an increase in the efficiency index, dividend index and total return index.
D
Sell
7/28/2016Downgrade
GlaxoSmithKline plc (GSK) was downgraded to D+ from C- on 7/28/2016 due to a substantial decline in the solvency index, efficiency index and dividend index. Debt to equity increased from 6.01 to 36.82, net income declined 254.68% from $403.46M to -$624.06M, and the quick ratio declined from 0.75 to 0.59.
GlaxoSmithKline plc (GSK) was downgraded to D+ from C- on 7/28/2016 due to a substantial decline in the solvency index, efficiency index and dividend index. Debt to equity increased from 6.01 to 36.82, net income declined 254.68% from $403.46M to -$624.06M, and the quick ratio declined from 0.75 to 0.59.
C
Hold
5/13/2016Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 5/13/2016 due to an increase in the total return index, volatility index and valuation index.
GlaxoSmithKline plc (GSK) was upgraded to C- from D+ on 5/13/2016 due to an increase in the total return index, volatility index and valuation index.
D
Sell
4/28/2016Downgrade
GlaxoSmithKline plc (GSK) was downgraded to D+ from C on 4/28/2016 due to a significant decline in the valuation index, growth index and solvency index. Debt to equity increased from 3.34 to 6.01, operating cash flow declined 68.4% from $2.28B to $719.65M, and the quick ratio declined from 0.86 to 0.75.
GlaxoSmithKline plc (GSK) was downgraded to D+ from C on 4/28/2016 due to a significant decline in the valuation index, growth index and solvency index. Debt to equity increased from 3.34 to 6.01, operating cash flow declined 68.4% from $2.28B to $719.65M, and the quick ratio declined from 0.86 to 0.75.
C
Hold
3/11/2016Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 3/11/2016 due to a large decline in the volatility index and total return index.
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 3/11/2016 due to a large decline in the volatility index and total return index.
C
Hold
1/29/2016Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 1/29/2016 due to a decline in the total return index.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 1/29/2016 due to a decline in the total return index.
B
Buy
1/15/2016Downgrade
GlaxoSmithKline plc (GSK) was downgraded to B- from B on 1/15/2016 due to a large decline in the total return index.
GlaxoSmithKline plc (GSK) was downgraded to B- from B on 1/15/2016 due to a large decline in the total return index.
B
Buy
12/31/2015Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 12/31/2015 due to a noticeable increase in the total return index and valuation index.
GlaxoSmithKline plc (GSK) was upgraded to B from B- on 12/31/2015 due to a noticeable increase in the total return index and valuation index.
B
Buy
11/13/2015Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 11/13/2015 due to a noticeable increase in the growth index, dividend index and total return index.
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 11/13/2015 due to a noticeable increase in the growth index, dividend index and total return index.
C
Hold
10/29/2015Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 10/29/2015 due to a decline in the dividend index, solvency index and total return index. Debt to equity increased from 2.45 to 3.12, and the quick ratio declined from 0.94 to 0.94.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 10/29/2015 due to a decline in the dividend index, solvency index and total return index. Debt to equity increased from 2.45 to 3.12, and the quick ratio declined from 0.94 to 0.94.
B
Buy
8/7/2015Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 8/7/2015 due to an increase in the total return index.
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 8/7/2015 due to an increase in the total return index.
C
Hold
6/29/2015Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 6/29/2015 due to a decline in the total return index and volatility index.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 6/29/2015 due to a decline in the total return index and volatility index.
B
Buy
5/15/2015Upgraded
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 5/15/2015 due to an increase in the dividend index, volatility index and valuation index.
GlaxoSmithKline plc (GSK) was upgraded to B- from C+ on 5/15/2015 due to an increase in the dividend index, volatility index and valuation index.
C
Hold
5/7/2015Upgraded
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 5/7/2015 due to a significant increase in the valuation index, solvency index and growth index. Earnings per share increased from $0.337 to $2.5184, EBIT increased 448.8% from $2.54B to $13.95B, and the quick ratio increased from 0.67 to 1.01.
GlaxoSmithKline plc (GSK) was upgraded to C+ from C on 5/7/2015 due to a significant increase in the valuation index, solvency index and growth index. Earnings per share increased from $0.337 to $2.5184, EBIT increased 448.8% from $2.54B to $13.95B, and the quick ratio increased from 0.67 to 1.01.
C
Hold
3/2/2015Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 3/2/2015 due to a substantial decline in the valuation index, growth index and solvency index. Debt to equity increased from 3.87 to 4.46.
GlaxoSmithKline plc (GSK) was downgraded to C from C+ on 3/2/2015 due to a substantial decline in the valuation index, growth index and solvency index. Debt to equity increased from 3.87 to 4.46.
C
Hold
10/24/2014Downgrade
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 10/24/2014 due to a major decline in the growth index, total return index and solvency index. Earnings per share declined from $0.2256 to $0.1369, debt to equity increased from 2.84 to 3.87, and EBIT declined 31.02% from $2.09B to $1.44B.
GlaxoSmithKline plc (GSK) was downgraded to C+ from B- on 10/24/2014 due to a major decline in the growth index, total return index and solvency index. Earnings per share declined from $0.2256 to $0.1369, debt to equity increased from 2.84 to 3.87, and EBIT declined 31.02% from $2.09B to $1.44B.
B
Buy
8/22/2014Downgrade
GlaxoSmithKline plc (GSK) was downgraded to B- from B on 8/22/2014 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.77 to 0.68, and debt to equity increased from 2.59 to 2.84.
GlaxoSmithKline plc (GSK) was downgraded to B- from B on 8/22/2014 due to a large decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.77 to 0.68, and debt to equity increased from 2.59 to 2.84.
B
Buy
5/2/2014Downgrade
GlaxoSmithKline plc (GSK) was downgraded to B from A- on 5/2/2014 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.8167 to $0.2267, operating cash flow declined 56.66% from $3.54B to $1.53B, and EBIT declined 43.16% from $3.52B to $2B.
GlaxoSmithKline plc (GSK) was downgraded to B from A- on 5/2/2014 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.8167 to $0.2267, operating cash flow declined 56.66% from $3.54B to $1.53B, and EBIT declined 43.16% from $3.52B to $2B.
A
Buy
4/22/2014Upgraded
GlaxoSmithKline plc (GSK) was upgraded to A- from B+ on 4/22/2014 due to a noticeable increase in the volatility index and total return index.
GlaxoSmithKline plc (GSK) was upgraded to A- from B+ on 4/22/2014 due to a noticeable increase in the volatility index and total return index.
B
Buy
4/7/2014Downgrade
GlaxoSmithKline plc (GSK) was downgraded to B+ from A- on 4/7/2014 due to a decline in the total return index and volatility index.
GlaxoSmithKline plc (GSK) was downgraded to B+ from A- on 4/7/2014 due to a decline in the total return index and volatility index.
A
Buy
3/3/2014Upgraded
GlaxoSmithKline plc (GSK) was upgraded to A- from B on 3/3/2014 due to a significant increase in growth, solvency and valuation. Earnings per share increased from $0.6112 to $1.6335, EBIT increased 25.7% from $2.8B to $3.52B, and the quick ratio increased from 0.67 to 0.8.
GlaxoSmithKline plc (GSK) was upgraded to A- from B on 3/3/2014 due to a significant increase in growth, solvency and valuation. Earnings per share increased from $0.6112 to $1.6335, EBIT increased 25.7% from $2.8B to $3.52B, and the quick ratio increased from 0.67 to 0.8.
NYSE
03/10/2025 11:09AM Eastern
Quotes delayed
